Nektar Therapeutics (BMV:NKTR)
Mexico · Delayed Price · Currency is MXN 693.50
-336.50 (-32.67%)
At close: Jan 12, 2026
Nektar Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 62.6 | 98.43 | 90.12 | 92.06 | 101.91 | 152.92 | |
Revenue Growth (YoY) | -32.79% | 9.21% | -2.10% | -9.67% | -33.36% | 33.41% |
Cost of Revenue | 7.98 | 30.69 | 33.77 | 21.64 | 24.9 | 19.48 |
Gross Profit | 54.62 | 67.74 | 56.35 | 70.42 | 77.01 | 133.44 |
Selling, General & Admin | 74.62 | 76.75 | 77.42 | 92.33 | 122.84 | 104.68 |
Research & Development | 116.36 | 120.91 | 114.16 | 218.32 | 400.27 | 408.68 |
Operating Expenses | 190.99 | 197.66 | 191.58 | 310.66 | 523.11 | 513.36 |
Operating Income | -136.36 | -129.92 | -135.23 | -240.24 | -446.1 | -379.92 |
Interest Expense | -26.57 | -28.11 | -25.33 | -28.91 | -47.31 | -37.12 |
Interest & Investment Income | 10.6 | 14.5 | 19.01 | 6.78 | 2.73 | 18.28 |
Other Non Operating Income (Expenses) | 0.27 | -0.39 | -1.15 | 33.31 | -8.19 | - |
EBT Excluding Unusual Items | -159.44 | -143.92 | -142.7 | -229.05 | -498.87 | -398.76 |
Merger & Restructuring Charges | -2.12 | -15.67 | -51.96 | -135.93 | - | - |
Impairment of Goodwill | - | - | -76.5 | - | - | - |
Gain (Loss) on Sale of Assets | 40.39 | 40.39 | -5.1 | - | - | - |
Other Unusual Items | - | - | - | - | -24.41 | -45.19 |
Pretax Income | -121.16 | -119.2 | -276.26 | -364.98 | -523.28 | -443.95 |
Income Tax Expense | -0.43 | -0.24 | -0.2 | 3.22 | 0.56 | 0.49 |
Net Income | -120.74 | -118.96 | -276.06 | -368.2 | -523.84 | -444.44 |
Net Income to Common | -120.74 | -118.96 | -276.06 | -368.2 | -523.84 | -444.44 |
Shares Outstanding (Basic) | 15 | 14 | 13 | 12 | 12 | 12 |
Shares Outstanding (Diluted) | 15 | 14 | 13 | 12 | 12 | 12 |
Shares Change (YoY) | 14.07% | 8.24% | 1.53% | 2.10% | 2.64% | 2.05% |
EPS (Basic) | -7.90 | -8.68 | -21.79 | -29.51 | -42.87 | -37.33 |
EPS (Diluted) | -7.90 | -8.68 | -21.79 | -29.55 | -42.90 | -37.33 |
Free Cash Flow | -190.35 | -177.18 | -193.47 | -309.68 | -427.65 | -320.55 |
Free Cash Flow Per Share | -12.46 | -12.92 | -15.27 | -24.82 | -35.00 | -26.92 |
Gross Margin | 87.26% | 68.82% | 62.53% | 76.50% | 75.57% | 87.26% |
Operating Margin | -217.83% | -131.99% | -150.05% | -260.97% | -437.76% | -248.45% |
Profit Margin | -192.87% | -120.86% | -306.31% | -399.98% | -514.03% | -290.64% |
Free Cash Flow Margin | -304.07% | -180.01% | -214.68% | -336.41% | -419.65% | -209.62% |
EBITDA | -135.2 | -125.53 | -127.41 | -227.21 | -431.96 | -365.74 |
EBITDA Margin | -215.97% | -127.53% | -141.38% | -246.81% | - | -239.18% |
D&A For EBITDA | 1.17 | 4.39 | 7.82 | 13.03 | 14.15 | 14.18 |
EBIT | -136.36 | -129.92 | -135.23 | -240.24 | -446.1 | -379.92 |
EBIT Margin | -217.83% | -131.99% | -150.05% | -260.97% | - | -248.45% |
Revenue as Reported | 62.6 | 98.43 | 90.12 | 92.06 | 101.91 | 152.92 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.